Media Library

Eric Allan, MD, discusses the clinical significance of his research and case study, “Low-Level Laser Therapy Reduces Pain in Patients with Head and Neck Cancer.”
Carryn Anderson, MD, discusses the clinical significance of her research on, “Severe Oral Mucositis Less Frequent, Briefer, Less Severe with Use of GC4419.”
Jennifer Brown, MD, PhD, expanded upon the results of her and her colleagues’ study of the hepatotoxic effects of idelalisib, particularly as frontline treatment of younger patients with chronic lymphocytic leukemia, which was presented at the 57th American Society of Hematology Annual Meeting & Exposition.
William A. Zellmer, BPharm, MPH, discusses how the 4th edition of the American Society of Health-System Pharmacists (ASHP) Foundation’s Pharmacy Forecast serves to improve the effectiveness of leaders in hospital and health-system pharmacy practice.
Lindsey B. Amerine, PharmD, MS, BCPS, discussed her practice’s process for formulary management and procurement of oncology medications at the 11th annual Hematology/Oncology Pharmacy Association conference.
Gunnar Birgegård, MD, PhD, discussed his team’s research comparing intravenous iron isomaltoside 1000 with oral iron sulphate monotherapy in patients with cancer and chemotherapy-induced anemia at the 2015 International Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Symposium on Supportive Care in Cancer.
Felicia Zook, PharmD, BCOP, discussed her medical practice’s successful development and implementation of a pharmacist-driven drug-monitoring protocol at the 11th annual Hematology/Oncology Pharmacy Association conference.
Michael Koraleski, PharmD, outlined the proposed standards of the newest US Pharmacopeial Convention (USP) Chapter 800 at the 11th annual Hematology/Oncology Pharmacy As­­sociation conference.

BERLIN—The field of oncology has come a long way in improving communication between healthcare providers and their patients with cancer—that is, unless the patient happens to be an adolescent.

From diagnosis through treatment, profound deficits still remain in the care of this age group, according to several presentations at the Joint Congress of the European Cancer Organisation and European Society for Medical Oncology.

Page 1 of 2
Results 1 - 10 of 13